2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2101

Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis
Abstract Number: 77

Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils
Abstract Number: 2873

Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Abstract Number: 621

ERAP1 Knockdown Affects HLA-B27 Misfolding and Endoplasmic Reticulum Stress in HLA-B27 Transgenic Rat Macrophages
Abstract Number: 764

ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications
Abstract Number: 1192

Erosions Detected By Magnet Resonance Imaging in Patients with Juvenile Idiopathic Arthritis (JIA) Are True Erosions As Visualized By Computed Tomography
Abstract Number: 1608

Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis
Abstract Number: 3005

Essential Role for Alternately Spliced Tenascin C and TLR4 Signaling in Persistent Organ Fibrosis
Abstract Number: 288

Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis
Abstract Number: 494

Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Abstract Number: 2687

Estrogen-Mediated STAT1 Activation By Estrogen Receptor a Induces TLR8 Expression: A Novel Pathogenic Mechanism in Systemic Lupus Erythematosus
Abstract Number: 509

Etanercept Have Better Drug Survival Than Monoclonal Antibodies in Rheumatoid Arthritis: Results of Single Center Hur-BIO Registry
Abstract Number: 2414

Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Abstract Number: 2558

Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
Abstract Number: 328

Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono-Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].